human oscc cell lines scc25 Search Results


97
ATCC oscc cells
Oscc Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+oscc+cell+lines+scc25/pm35999496-202-0-7?v=ATCC
Average 97 stars, based on 1 article reviews
oscc cells - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier

98
ATCC human oscc cells
Human Oscc Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+oscc+cell+lines+scc25/10__4314_slash_tjpr__v22i1__7-45-0-12?v=ATCC
Average 98 stars, based on 1 article reviews
human oscc cells - by Bioz Stars, 2026-08
98/100 stars
  Buy from Supplier

96
ATCC human oscc cell lines
Human Oscc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+oscc+cell+lines+scc25/pm30071298-42-0-11?v=ATCC
Average 96 stars, based on 1 article reviews
human oscc cell lines - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

86
Procell Inc human oscc cell lines scc25
Human Oscc Cell Lines Scc25, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+oscc+cell+lines+scc25/pm42286153-186-1-11?v=Procell+Inc
Average 86 stars, based on 1 article reviews
human oscc cell lines scc25 - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

90
BioResource International Inc human oscc cell lines scc4
CX3CL1 was upregulated in oral squamous cell carcinoma <t>(OSCC)</t> tissue and associated with clinical disease stages in human OSCC. (A) Correlation CX3CL1 gene expression with the normal and tumour cells using GEO microarray 3524 OSCC tissue samples. (B) CX3CL1 expression profiles in 497 OSCC tissue specimens were analysed obtained from the Cancer Genome Atlas (TCGA) database. (C,D) OSCC specimens were subjected to IHC staining. (E) Kaplan–Meier survival analysis of the associations between high or low plasma levels of CX3CL1 expression and overall survival of OSCC patients. * p < 0.05 compared with controls.
Human Oscc Cell Lines Scc4, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+oscc+cell+lines+scc25/pmc10243164-35-1-14?v=BioResource+International+Inc
Average 90 stars, based on 1 article reviews
human oscc cell lines scc4 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

99
ATCC oscc human tumor cells
CX3CL1 was upregulated in oral squamous cell carcinoma <t>(OSCC)</t> tissue and associated with clinical disease stages in human OSCC. (A) Correlation CX3CL1 gene expression with the normal and tumour cells using GEO microarray 3524 OSCC tissue samples. (B) CX3CL1 expression profiles in 497 OSCC tissue specimens were analysed obtained from the Cancer Genome Atlas (TCGA) database. (C,D) OSCC specimens were subjected to IHC staining. (E) Kaplan–Meier survival analysis of the associations between high or low plasma levels of CX3CL1 expression and overall survival of OSCC patients. * p < 0.05 compared with controls.
Oscc Human Tumor Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+oscc+cell+lines+scc25/pm39814222-61-0-25?v=ATCC
Average 99 stars, based on 1 article reviews
oscc human tumor cells - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

90
SAS institute human oscc cell line hsc-2
CX3CL1 was upregulated in oral squamous cell carcinoma <t>(OSCC)</t> tissue and associated with clinical disease stages in human OSCC. (A) Correlation CX3CL1 gene expression with the normal and tumour cells using GEO microarray 3524 OSCC tissue samples. (B) CX3CL1 expression profiles in 497 OSCC tissue specimens were analysed obtained from the Cancer Genome Atlas (TCGA) database. (C,D) OSCC specimens were subjected to IHC staining. (E) Kaplan–Meier survival analysis of the associations between high or low plasma levels of CX3CL1 expression and overall survival of OSCC patients. * p < 0.05 compared with controls.
Human Oscc Cell Line Hsc 2, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+oscc+cell+lines+scc25/10__3892_slash_or_00000085-23-2-11?v=SAS+institute
Average 90 stars, based on 1 article reviews
human oscc cell line hsc-2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

scc 25  (DSMZ)
94
DSMZ scc 25
CX3CL1 was upregulated in oral squamous cell carcinoma <t>(OSCC)</t> tissue and associated with clinical disease stages in human OSCC. (A) Correlation CX3CL1 gene expression with the normal and tumour cells using GEO microarray 3524 OSCC tissue samples. (B) CX3CL1 expression profiles in 497 OSCC tissue specimens were analysed obtained from the Cancer Genome Atlas (TCGA) database. (C,D) OSCC specimens were subjected to IHC staining. (E) Kaplan–Meier survival analysis of the associations between high or low plasma levels of CX3CL1 expression and overall survival of OSCC patients. * p < 0.05 compared with controls.
Scc 25, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+oscc+cell+lines+scc25/pm39656562-60-9-23?v=DSMZ
Average 94 stars, based on 1 article reviews
scc 25 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

90
SAS institute oscc lines scc25
Findings from eligible studies assessing extracellular vesicles (EVs) in <t> oral squamous cell carcinoma </t> <t> (OSCC) </t> and oral potentially malignant disorders (OPMD) clinical cohort samples.
Oscc Lines Scc25, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+oscc+cell+lines+scc25/pmc07072764-29-8-11?v=SAS+institute
Average 90 stars, based on 1 article reviews
oscc lines scc25 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

90
JCRB Cell Bank hsc-3 cells
Findings from eligible studies assessing extracellular vesicles (EVs) in <t> oral squamous cell carcinoma </t> <t> (OSCC) </t> and oral potentially malignant disorders (OPMD) clinical cohort samples.
Hsc 3 Cells, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+oscc+cell+lines+scc25/10__3892_slash_or_00000275-47-2-6?v=JCRB+Cell+Bank
Average 90 stars, based on 1 article reviews
hsc-3 cells - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


CX3CL1 was upregulated in oral squamous cell carcinoma (OSCC) tissue and associated with clinical disease stages in human OSCC. (A) Correlation CX3CL1 gene expression with the normal and tumour cells using GEO microarray 3524 OSCC tissue samples. (B) CX3CL1 expression profiles in 497 OSCC tissue specimens were analysed obtained from the Cancer Genome Atlas (TCGA) database. (C,D) OSCC specimens were subjected to IHC staining. (E) Kaplan–Meier survival analysis of the associations between high or low plasma levels of CX3CL1 expression and overall survival of OSCC patients. * p < 0.05 compared with controls.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 was upregulated in oral squamous cell carcinoma (OSCC) tissue and associated with clinical disease stages in human OSCC. (A) Correlation CX3CL1 gene expression with the normal and tumour cells using GEO microarray 3524 OSCC tissue samples. (B) CX3CL1 expression profiles in 497 OSCC tissue specimens were analysed obtained from the Cancer Genome Atlas (TCGA) database. (C,D) OSCC specimens were subjected to IHC staining. (E) Kaplan–Meier survival analysis of the associations between high or low plasma levels of CX3CL1 expression and overall survival of OSCC patients. * p < 0.05 compared with controls.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Gene Expression, Microarray, Expressing, Immunohistochemistry, Clinical Proteomics

CX3CL1 upregulates human oral squamous cell carcinoma (OSCC) cell migration and invasion. (A‐C) OSCC cells were incubated with different concentrations of CX3CL1 for 24 h; then, cell migration was assessed using the (A) in vitro wound‐healing assay, (B,C) the Transwell assay. (D) Quantified result of cell migration with CX3CL1 neutralizing antibody. (E) Quantified result of cell invasion with CX3CL1 neutralizing antibody. Results are expressed as the mean ± SD of four independent experiments. * p < 0.05 as compared with controls.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 upregulates human oral squamous cell carcinoma (OSCC) cell migration and invasion. (A‐C) OSCC cells were incubated with different concentrations of CX3CL1 for 24 h; then, cell migration was assessed using the (A) in vitro wound‐healing assay, (B,C) the Transwell assay. (D) Quantified result of cell migration with CX3CL1 neutralizing antibody. (E) Quantified result of cell invasion with CX3CL1 neutralizing antibody. Results are expressed as the mean ± SD of four independent experiments. * p < 0.05 as compared with controls.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Migration, Incubation, In Vitro, Wound Healing Assay, Transwell Assay

CX3CL1 activates tumour cell migration via the ICAM‐1 expression in human oral squamous cell carcinoma (OSCC) cells. (A) ICAM‐1 expression in the normal and tumour cells obtained from the TCGA dataset analysis. (B) VCAM‐1 expression in the normal and tumour cells obtained from the TCGA dataset analysis. (C) Correlation analysis of CX3CL1 and ICAM‐1 expression using the TIMER2.0 database. (D) Correlation analysis of CX3CL1 and VCAM‐1 expression using the TIMER2.0 database. (E) Quantified result of ICAM‐1 gene expression with CX3CL1 recombinant protein (30 ng/mL) treatment. (F) Quantified result of VCAM‐1 gene expression with CX3CL1 recombinant protein (30 ng/mL) treatment. (G) Protein expression of ICAM‐1 with concentration‐depended CX3CL1 treatment. (H) Protein expression of VCAM‐1 with concentration‐depended CX3CL1 treatment. (I) Quantified result of cell migration with ICAM‐1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. (J) Quantified result of cell migration with ICAM‐1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 activates tumour cell migration via the ICAM‐1 expression in human oral squamous cell carcinoma (OSCC) cells. (A) ICAM‐1 expression in the normal and tumour cells obtained from the TCGA dataset analysis. (B) VCAM‐1 expression in the normal and tumour cells obtained from the TCGA dataset analysis. (C) Correlation analysis of CX3CL1 and ICAM‐1 expression using the TIMER2.0 database. (D) Correlation analysis of CX3CL1 and VCAM‐1 expression using the TIMER2.0 database. (E) Quantified result of ICAM‐1 gene expression with CX3CL1 recombinant protein (30 ng/mL) treatment. (F) Quantified result of VCAM‐1 gene expression with CX3CL1 recombinant protein (30 ng/mL) treatment. (G) Protein expression of ICAM‐1 with concentration‐depended CX3CL1 treatment. (H) Protein expression of VCAM‐1 with concentration‐depended CX3CL1 treatment. (I) Quantified result of cell migration with ICAM‐1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. (J) Quantified result of cell migration with ICAM‐1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Migration, Expressing, Gene Expression, Recombinant, Concentration Assay, Control

CX3CL1 upregulates cell motility and ICAM‐1 expression via its receptor CX3CR1. (A) Levels of CX3CR1 mRNA expression in normal tongue tissue and human oral squamous cell carcinoma (OSCC) tumour tissue were analysed using records from the GEO data set GSE13601. (B) Levels of CX3CR1 mRNA expression in different N stages of OSCC tumour tissue were analysed using records from the GEO data set GSE78060. (C) Quantified result of cell movement with CX3CR1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. (D) Quantified result of cell migration with CX3CR1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. (E) Quantified resulting of ICAM‐1 expression with CX3CR1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. (F) Quantified result of cell movement with CX3CR1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. (G) Quantified result of cell migration with CX3CR1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. (H) Quantified result of ICAM‐1 expression with CX3CR1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 upregulates cell motility and ICAM‐1 expression via its receptor CX3CR1. (A) Levels of CX3CR1 mRNA expression in normal tongue tissue and human oral squamous cell carcinoma (OSCC) tumour tissue were analysed using records from the GEO data set GSE13601. (B) Levels of CX3CR1 mRNA expression in different N stages of OSCC tumour tissue were analysed using records from the GEO data set GSE78060. (C) Quantified result of cell movement with CX3CR1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. (D) Quantified result of cell migration with CX3CR1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. (E) Quantified resulting of ICAM‐1 expression with CX3CR1 neutralizing antibody and CX3CL1 recombinant protein (30 ng/mL) treatment. (F) Quantified result of cell movement with CX3CR1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. (G) Quantified result of cell migration with CX3CR1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. (H) Quantified result of ICAM‐1 expression with CX3CR1 siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Expressing, Recombinant, Migration, Control

CX3CL1 triggers the phosphorylation of PLCβ/PKCα/c‐Src to signal the cell movement, migration and ICAM‐1 expression in human oral squamous cell carcinoma (OSCC) cells. (A‐C) Quantified result of cell movement, cell migration and ICAM‐1 expression with signalling inhibitors and CX3CL1 recombinant protein (30 ng/mL) treatment. (D‐E) Protein expression of phosphorylated PLCβ, PKCα and c‐Src with CX3CL1 recombinant protein (30 ng/mL) treatment in SCC4 cell and SAS cell. (F‐H) Quantified result of cell movement, cell migration and ICAM‐1 expression with PLCβ, PKCα or c‐Src siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 triggers the phosphorylation of PLCβ/PKCα/c‐Src to signal the cell movement, migration and ICAM‐1 expression in human oral squamous cell carcinoma (OSCC) cells. (A‐C) Quantified result of cell movement, cell migration and ICAM‐1 expression with signalling inhibitors and CX3CL1 recombinant protein (30 ng/mL) treatment. (D‐E) Protein expression of phosphorylated PLCβ, PKCα and c‐Src with CX3CL1 recombinant protein (30 ng/mL) treatment in SCC4 cell and SAS cell. (F‐H) Quantified result of cell movement, cell migration and ICAM‐1 expression with PLCβ, PKCα or c‐Src siRNA and CX3CL1 recombinant protein (30 ng/mL) treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Phospho-proteomics, Migration, Expressing, Recombinant, Control

CX3CL1 promotes the phosphorylation of c‐Jun to upregulate the cell motility and ICAM‐1 expression in human oral squamous cell carcinoma (OSCC) cells. (A) Quantified result of CX3CL1‐induced cell movement with c‐Jun inhibitors (B) Quantified result of CX3CL1‐induced cell migration with c‐Jun inhibitors (C) Quantified result of CX3CL1‐induced ICAM‐1 expression with c‐Jun inhibitors (D) Protein expression of phosphorylated c‐Jun with CX3CL1 recombinant protein (30 ng/mL) treatment. (E) Quantified result of CX3CL1‐induced cell movement with c‐Jun siRNA treatment. (F) Quantified result of CX3CL1‐induced cell migration with c‐Jun siRNA treatment. (G) Quantified result of CX3CL1‐induced ICAM‐1 expression with c‐Jun siRNA treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 promotes the phosphorylation of c‐Jun to upregulate the cell motility and ICAM‐1 expression in human oral squamous cell carcinoma (OSCC) cells. (A) Quantified result of CX3CL1‐induced cell movement with c‐Jun inhibitors (B) Quantified result of CX3CL1‐induced cell migration with c‐Jun inhibitors (C) Quantified result of CX3CL1‐induced ICAM‐1 expression with c‐Jun inhibitors (D) Protein expression of phosphorylated c‐Jun with CX3CL1 recombinant protein (30 ng/mL) treatment. (E) Quantified result of CX3CL1‐induced cell movement with c‐Jun siRNA treatment. (F) Quantified result of CX3CL1‐induced cell migration with c‐Jun siRNA treatment. (G) Quantified result of CX3CL1‐induced ICAM‐1 expression with c‐Jun siRNA treatment. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Phospho-proteomics, Expressing, Migration, Recombinant, Control

CX3CL1 promotes the translocation of c‐Jun and promoter binding of AP‐1 formation in human oral squamous cell carcinoma (OSCC) cells. (A) Immunofluorescent staining showed that c‐Jun translocated into the nucleus after cell were treated with CX3CL1; nuclear translocation was prevented when the cells were pre‐treated with CX3CR1 mAb, U73122, GF109203 or PP2. (B) Quantified analysis of c‐Jun activation with CX3CL1 using Western blot. (C) CX3CL1 treatment upregulated AP‐1 luciferase activity. (D) Quantified analysis of AP‐1 luciferase activity with specific inhibitors and CX3CL1 recombinant protein (30 ng/mL) treatment. (E) Chromatin immunoprecipitation analysis of c‐Jun and AP‐1 promoter binding site with neutralizing antibody and specific inhibitors. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CX3CL1 induces cell migration and invasion through ICAM ‐1 expression in oral squamous cell carcinoma cells

doi: 10.1111/jcmm.17750

Figure Lengend Snippet: CX3CL1 promotes the translocation of c‐Jun and promoter binding of AP‐1 formation in human oral squamous cell carcinoma (OSCC) cells. (A) Immunofluorescent staining showed that c‐Jun translocated into the nucleus after cell were treated with CX3CL1; nuclear translocation was prevented when the cells were pre‐treated with CX3CR1 mAb, U73122, GF109203 or PP2. (B) Quantified analysis of c‐Jun activation with CX3CL1 using Western blot. (C) CX3CL1 treatment upregulated AP‐1 luciferase activity. (D) Quantified analysis of AP‐1 luciferase activity with specific inhibitors and CX3CL1 recombinant protein (30 ng/mL) treatment. (E) Chromatin immunoprecipitation analysis of c‐Jun and AP‐1 promoter binding site with neutralizing antibody and specific inhibitors. Results are expressed as the mean ± SD of four independent experiments. *, p < 0.05 and #, p < 0.05 as compared to control and CX3CL1 treatment.

Article Snippet: Three human OSCC cell lines (SCC4, SCC25 and SAS cells) were acquired from the Bioresource Collection and Research Center (BCRC).

Techniques: Translocation Assay, Binding Assay, Staining, Activation Assay, Western Blot, Luciferase, Activity Assay, Recombinant, Chromatin Immunoprecipitation, Control

Findings from eligible studies assessing extracellular vesicles (EVs) in  oral squamous cell carcinoma   (OSCC)  and oral potentially malignant disorders (OPMD) clinical cohort samples.

Journal: International Journal of Molecular Sciences

Article Title: Extracellular Vesicles in Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review

doi: 10.3390/ijms21041197

Figure Lengend Snippet: Findings from eligible studies assessing extracellular vesicles (EVs) in oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMD) clinical cohort samples.

Article Snippet: [ ] , Primary CAFs and NOFs, , OSCC lines (HSC3, SAS, SCC15, SCC25) , CAF-EVS significantly increased the invasive, migration and apoptosis rate of HSC-3, SAS and SCC-15 but not SCC-25 with HSC-3 the most was most responsive to pooled CAF-EVs with deeper invasion, small tumour islands.

Techniques: Western Blot, Enzyme-linked Immunosorbent Assay, Concentration Assay, Expressing, Real-time Polymerase Chain Reaction, Spectroscopy, IR Spectroscopy, Microarray, Comparison, Flow Cytometry, Clinical Proteomics

Findings from eligible studies assessing EVs in cell-based samples.

Journal: International Journal of Molecular Sciences

Article Title: Extracellular Vesicles in Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review

doi: 10.3390/ijms21041197

Figure Lengend Snippet: Findings from eligible studies assessing EVs in cell-based samples.

Article Snippet: [ ] , Primary CAFs and NOFs, , OSCC lines (HSC3, SAS, SCC15, SCC25) , CAF-EVS significantly increased the invasive, migration and apoptosis rate of HSC-3, SAS and SCC-15 but not SCC-25 with HSC-3 the most was most responsive to pooled CAF-EVs with deeper invasion, small tumour islands.

Techniques: Derivative Assay, Migration, Produced, Expressing, Transformation Assay, Isolation, Phospho-proteomics, Plasmid Preparation, Incubation, Activation Assay, Cell Culture, Inhibition, Transfection

Known roles and interactions of EVs in OSCC.

Journal: International Journal of Molecular Sciences

Article Title: Extracellular Vesicles in Oral Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review

doi: 10.3390/ijms21041197

Figure Lengend Snippet: Known roles and interactions of EVs in OSCC.

Article Snippet: [ ] , Primary CAFs and NOFs, , OSCC lines (HSC3, SAS, SCC15, SCC25) , CAF-EVS significantly increased the invasive, migration and apoptosis rate of HSC-3, SAS and SCC-15 but not SCC-25 with HSC-3 the most was most responsive to pooled CAF-EVs with deeper invasion, small tumour islands.

Techniques: